Michael John McElhaugh

All filings by Michael John McElhaugh on record concern Arbutus Biopharma Corporation. Between 23 July 2020 and 14 February 2025, the trades on record add up to 5 filings.

No open-market purchase appears, only 3 sales worth €259k. Other entries cover 2 share grants.

On 19 February 2025 came the latest disclosure, a share grant in Arbutus Biopharma Corporation. The median gap between a trade and its publication by SEDI is 5 days. That lag is the time during which only the insider knows about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.